Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

A live webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at https://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist.

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...